ReviewDiagnostics (Basel, Switzerland)2026
Contrast Sensitivity Impairment in Diabetic Retinopathy: Clinical and Structural Correlates.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic retinopathy (DR) is one of the main causes of vision impairment globally, and it is increasingly recognized as a neurovascular disease characterized by both microvascular and neural dysfunction. Traditional assessment approaches primarily focus on structural retinal alterations and visual acuity, which may fail to identify early functional impairments. Contrast sensitivity (CS), which measures the capacity to distinguish subtle luminance differences, is increasingly recognized as an early manifestation of retinal dysfunction in diabetes mellitus. This narrative review seeks to describe current knowledge on the role of CS in DR, including its pathophysiological foundation, clinical importance, and link to structural retinal alterations. A systematic literature search of PubMed, Scopus, and Google Scholar (2000-2026) was performed to identify studies on CS in diabetes mellitus and diabetic retinopathy. Multiple investigations found that diabetic patients, including those with no clinically evident DR and normal visual acuity, had lower contrast sensitivity. CS impairment was associated with retinal neurodegeneration, ganglion cell dysfunction, microvascular alterations, and diabetic macular edema severity. OCT and OCT-A findings showed important structure-function correlations between reduced CS and retinal thinning, capillary dropout, and impaired perfusion. CS testing may provide additional functional information beyond standard visual acuity assessment and may improve early disease detection and monitoring. In conclusion, contrast sensitivity represents a promising functional biomarker for early diabetic retinal dysfunction and may complement structural imaging and visual acuity testing in DR evaluation. Although methodological variability currently limits widespread clinical implementation, advances in digital technologies and multimodal assessment strategies may facilitate its future integration into routine ophthalmologic practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.